Bill Oxford Recursion Pharmaceuticals (NASDAQ:RXRX) is a clinical-stage biotechnology company that gained fame in July 2023 when it benefited from a $50 million investment by NVIDIA (NASDAQ:NVDA). As a result, the market cap doubled to around $3.2 billion as shown below, but, after some ups and downs, the stock has since retrenched and is trading at less than $9. Data by YCharts This thesis aims to show that it is a buy at the current price because Recursion operates more as a TechBio than biotech. The  ...